XTX Topco Ltd Purchases 10,117 Shares of Exelixis, Inc. (NASDAQ:EXEL)

Key Points

• XTX Topco Ltd increased its stake in Exelixis, Inc. by 32.7% during the first quarter, owning a total of 41,066 shares valued at approximately $1.5 million.
• Several institutional investors also raised their positions in Exelixis, with Harvest Fund Management Co. Ltd increasing its position by 64.2%.
• Exelixis reported a quarterly EPS of $0.75, exceeding analyst expectations of $0.63, though revenue decreased by 10.8% year-over-year.

XTX Topco Ltd raised its holdings in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 32.7% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 41,066 shares of the biotechnology company's stock after purchasing an additional 10,117 shares during the period. XTX Topco Ltd's holdings in Exelixis were worth $1,516,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the stock. Harvest Fund Management Co. Ltd boosted its position in shares of Exelixis by 64.2% in the first quarter. Harvest Fund Management Co. Ltd now owns 21,674 shares of the biotechnology company's stock worth $799,000 after buying an additional 8,472 shares during the period. Federated Hermes Inc. increased its holdings in shares of Exelixis by 18.3% in the 1st quarter. Federated Hermes Inc. now owns 483,738 shares of the biotechnology company's stock valued at $17,860,000 after acquiring an additional 74,806 shares during the last quarter. Picton Mahoney Asset Management raised its holdings in shares of Exelixis by 37,669.8% during the first quarter. Picton Mahoney Asset Management now owns 16,241 shares of the biotechnology company's stock worth $599,000 after purchasing an additional 16,198 shares during the period. LPL Financial LLC lifted its holdings in Exelixis by 74.5% in the first quarter. LPL Financial LLC now owns 187,097 shares of the biotechnology company's stock worth $6,908,000 after acquiring an additional 79,885 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Exelixis by 3.9% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 65,913 shares of the biotechnology company's stock worth $2,434,000 after buying an additional 2,466 shares during the last quarter. Institutional investors and hedge funds own 85.27% of the company's stock.

Wall Street Analysts Forecast Growth

EXEL has been the subject of a number of recent analyst reports. Wall Street Zen lowered Exelixis from a "strong-buy" rating to a "buy" rating in a report on Saturday. William Blair restated an "outperform" rating on shares of Exelixis in a research note on Tuesday, July 29th. HC Wainwright increased their target price on shares of Exelixis from $47.00 to $53.00 and gave the company a "buy" rating in a research report on Monday, June 30th. JMP Securities reaffirmed a "market outperform" rating and issued a $50.00 price target on shares of Exelixis in a research note on Tuesday, July 29th. Finally, Jefferies Financial Group set a $50.00 target price on Exelixis and gave the stock a "buy" rating in a report on Tuesday, June 24th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and fourteen have issued a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $44.44.

Exelixis Stock Performance

Shares of Exelixis stock traded up $0.39 during trading on Tuesday, reaching $37.20. The company's stock had a trading volume of 1,862,260 shares, compared to its average volume of 3,092,528. Exelixis, Inc. has a one year low of $23.21 and a one year high of $49.62. The firm has a market cap of $10.01 billion, a price-to-earnings ratio of 17.91, a price-to-earnings-growth ratio of 0.77 and a beta of 0.29. The business's fifty day moving average price is $42.82 and its 200-day moving average price is $38.93.

Exelixis (NASDAQ:EXEL - Get Free Report) last announced its quarterly earnings data on Monday, July 28th. The biotechnology company reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.63 by $0.12. The company had revenue of $568.26 million for the quarter, compared to analyst estimates of $574.36 million. Exelixis had a return on equity of 27.47% and a net margin of 27.01%. Exelixis's revenue for the quarter was down 10.8% compared to the same quarter last year. During the same quarter last year, the firm earned $0.84 EPS. Sell-side analysts anticipate that Exelixis, Inc. will post 2.04 EPS for the current year.

Insider Transactions at Exelixis

In other Exelixis news, Director Stelios Papadopoulos sold 36,508 shares of Exelixis stock in a transaction on Thursday, May 15th. The stock was sold at an average price of $44.35, for a total value of $1,619,129.80. Following the completion of the transaction, the director owned 1,279,416 shares in the company, valued at approximately $56,742,099.60. The trade was a 2.77% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Patrick J. Haley sold 126,383 shares of the stock in a transaction dated Thursday, May 15th. The stock was sold at an average price of $47.96, for a total transaction of $6,061,328.68. Following the sale, the executive vice president directly owned 446,459 shares in the company, valued at approximately $21,412,173.64. This represents a 22.06% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 456,605 shares of company stock valued at $20,966,005. 2.85% of the stock is owned by company insiders.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.